In a groundbreaking meta-analysis published in Translational Psychiatry, researchers have unveiled compelling evidence that caffeine, a widely consumed psychoactive substance, may exert significant effects on neuroinflammation, with profound implications for anxiety and depression disorders. This systematic review synthesizes data from rodent models, providing arguably the most comprehensive examination to date of caffeine’s influence on the neuroimmune landscape of neuropsychiatric conditions. Given the global prevalence of anxiety and depression, understanding the immunomodulatory capacities of caffeine could revolutionize therapeutic strategies and preventative approaches.
The researchers meticulously analyzed published rodent studies that assessed caffeine’s impact on neuroinflammatory markers and behavioral outcomes related to anxiety and depression. Neuroinflammation is increasingly recognized as a critical pathological contributor to mood disorders, characterized by an overactive immune response in the central nervous system that disrupts normal neuronal functioning. Microglia, the brain’s resident immune cells, become dysregulated during neuroinflammatory states, releasing proinflammatory cytokines that can exacerbate depressive and anxious behaviors. Against this biological backdrop, caffeine emerges as a potential neuroimmune modulator with considerable promise.
Central to the findings is caffeine’s capacity to attenuate proinflammatory cytokine production in key brain areas implicated in mood regulation, such as the hippocampus and prefrontal cortex. These regions are profoundly affected in depressive and anxious states, often exhibiting elevated levels of interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and other inflammatory mediators. The reviewed studies consistently showed that caffeine intake resulted in the downregulation of these cytokines, correlating with reduced behavioral markers of anxiety and depression in rodents. This immunosuppressive effect is thought to be mediated by caffeine’s antagonistic actions on adenosine receptors, which are pivotal in immune cell signaling within the central nervous system.
Moreover, the systematic review highlights caffeine’s role in modulating microglial activation states. Microglia can shift between proinflammatory (M1) and anti-inflammatory (M2) phenotypes, a balance crucial for brain homeostasis. Rodent models treated with caffeine demonstrated a shift toward the M2 phenotype, indicative of reduced inflammatory activity and enhanced neuroprotection. This phenotypic modulation may underlie the neuroprotective effects observed behaviorally, as animals exhibited reductions in anxiety-like and depression-like behaviors following caffeine administration in multiple experimental paradigms.
The translational relevance of these findings cannot be overstated. Anxiety and depression remain among the most debilitating mental health disorders worldwide, with current pharmacotherapies often plagued by limited efficacy and considerable side effects. Caffeine’s ability to modulate neuroinflammation presents a promising adjunct or alternative pathway worth clinical exploration. Importantly, the widespread societal consumption of caffeine makes these findings immediately impactful, suggesting that everyday dietary choices might influence mental health outcomes through neuroimmune mechanisms.
Another intriguing dimension emerging from the analysis is caffeine’s temporal and dose-dependent effects. The reviewed rodent studies indicate that moderate doses of caffeine yield the most beneficial anti-inflammatory and behavioral outcomes, whereas very high doses fail to confer additional advantage and might even exacerbate neuroinflammation. This biphasic response underscores the necessity to delineate optimal dosing regimens for potential therapeutic applications, balancing efficacy against side effect profiles.
The methodological rigor of the meta-analysis lends strong credibility to the conclusions. By including diverse rodent species, multiple caffeine administration protocols, and systematically controlling for confounding variables, the researchers have isolated consistent trends that transcend individual study limitations. Nevertheless, the review calls for more nuanced investigations into sex differences, age-related responsiveness, and the long-term consequences of chronic caffeine exposure on neuroimmune parameters, all of which remain underexplored.
Furthermore, the neurocircuitry involved in caffeine’s anti-inflammatory effects are intertwined with metabolic and neuroendocrine pathways. Caffeine’s interaction with hypothalamic-pituitary-adrenal (HPA) axis dynamics, oxidative stress modulators, and brain-derived neurotrophic factor (BDNF) expression may synergize with its immunomodulatory properties to alleviate mood disorders. This multifaceted mechanism suggests that caffeine’s effects are not simply inhibitory but involve orchestration of multiple neurobiological systems critical to emotional regulation.
Behavioral analyses consolidated within the review also affirm caffeine’s anxiolytic and antidepressant-like effects, as gauged through standard paradigms such as the elevated plus maze, forced swim test, and open field test. Rodents chronically exposed to caffeine displayed increased exploratory behavior and reduced signs of behavioral despair, reinforcing the functional relevance of the biochemical changes identified. Such findings bridge preclinical and clinical domains, indicating caffeine’s potential to improve quality-of-life outcomes through biological modulation of neuroinflammation.
However, the authors prudently caution that rodent models, while invaluable, cannot wholly replicate the complexity of human neuropsychiatric disorders. Future clinical trials are imperative to validate these preclinical findings and optimize caffeine-based interventions. These should incorporate advanced neuroimaging, inflammatory biomarker quantification, and longitudinal mental health assessments to substantiate caffeine’s therapeutic utility and safety in diverse populations.
In summary, this systematic review offers unprecedented insight into caffeine as a modulator of neuroinflammation with tangible impacts on anxiety and depression phenotypes. The convergence of neuroimmune science with widely accessible dietary compounds heralds a paradigm shift in how mental health disorders might be prevented and treated. As society grapples with rising mental health burdens, such accessible interventions are urgently needed, underscoring the import of continuing rigorous translational neuroscience research.
The implications extend beyond psychiatry, opening avenues for caffeine’s application in other neuroinflammatory and neurodegenerative diseases. By dissecting molecular and cellular mechanisms underpinning its effects, scientists may engineer caffeine analogs or adjunctive therapies that harness its benefits while minimizing adverse outcomes. This research sets a high standard for future investigations into nutraceutical and pharmacological modulation of brain immune responses.
Ultimately, the review by da Silva Neves, de Mattos, Oliveira-Nazareth, and colleagues elegantly synthesizes and advances our understanding of caffeine’s role within the neuroimmune interface. It challenges researchers and clinicians alike to reconsider the potentials of everyday substances in reshaping brain health landscapes, potentially transforming public health approaches with far-reaching consequences.
Subject of Research: Effects of caffeine on neuroinflammation in anxiety and depression
Article Title: Effects of caffeine on neuroinflammation in anxiety and depression: a systematic review of rodent studies
Article References:
da Silva Neves, L., de Mattos, G.V.R.M., Oliveira-Nazareth, Y. et al. Effects of caffeine on neuroinflammation in anxiety and depression: a systematic review of rodent studies. Transl Psychiatry 15, 477 (2025). https://doi.org/10.1038/s41398-025-03668-x
Image Credits: AI Generated
DOI: 17 November 2025
